WO2001038370A1

WO2001038370A1 - A novel polypeptide-transcriptional activator subunit 49 and the polynucleotide encoding said polypeptide

Info

Publication number: WO2001038370A1
Application number: PCT/CN2000/000474
Authority: WO
Inventors: Yumin Mao; Yi Xie
Original assignee: Bioroad Gene Development Ltd. Shanghai
Priority date: 1999-11-24
Filing date: 2000-11-20
Publication date: 2001-05-31
Also published as: CN1297908A; AU1687001A

Abstract

The invention discloses a new kind of polypeptide-transcriptional activator subunit 49 and the polynucleotide encoding said polypeptide and a process for producing the polypeptide by recombinant methods. It also discloses the method of applying the polypeptide for the treatment of various kinds of diseases, such as muscular dystrophy, genisis dysfunction and cancer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said transcriptional activator subunit 49.

Description

Manual

A new polypeptide one transcription activation protein subunit 49 and a polynucleotide encoding the polypeptide TECHNICAL FIELD

The present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide transcript activating protein subunit 49, and a polynucleotide sequence encoding the polypeptide. The invention also relates to a preparation method and application of the polynucleotide and the polypeptide. Background technique

Transcription of eukaryotic cells requires two types of proteins. Universal transcription factor and activating protein. The former directs basic transcription, while the latter is responsible for cell-, tissue-, and gene-specific transcription that occur after receiving various stimuli. GABP is a transcriptional activator protein and it is a member of the ETS family. It is composed of two subunits (X and β. The -X00 subunit of the X subunit has an ETS domain, which can be combined with the promoter's A / CGGAA / TA / GY sequence and activate RNA transcription. -The 4 cysteine at C00H are redox regulated sites, and the modification of these sites affects the binding of protein to DNA and the binding of a and β subunits. (1) Yurrii Chinenov, Tonya Schmidt, ea tl (1998) J Biol Chem, 273 (11) 6203-6209

The beta subunit contains 4.5 tandem ankyrin repeats. Each repeat unit consists of a pair of antiparallel curling helices and a loop with a type I corner at one end. These structures mainly mediate heterodimerization with the (X) subunit, thereby strengthening the binding of the (A) subunit to D. (2) Adrian H. Batchelor, Derek E. Piper, Fabienne Charles de la Brousse, Steven L. McKnight , Cynthia Wolberger (1998) science 279: 1037-1041

It has been discovered that GABP is an activator of the utrophin promoter. Utrophin is a nutrient protein found at the nerve-muscle junction. Therefore, GABP can increase the expression of utrophinD, so as to treat Duchenne muscular dystrophy. (3) Khurana TS, Rosmarin AG, Shang J et al. (1999) Mol Biol Cell 10 (6): 2075-86

GABP is also involved in the activation of the 0TR (oxytocin receptor) gene promoter, and oxytocin mediates labor and ejaculation. Therefore GABP can be used to regulate reproductive function. (4) Hoare S, Copland J A, Wood T G et al (1999) Endocr inology 140 (5) 2268-79

In addition, GABP is also involved in the transcriptional activation of tumor necrosis factor, which is used for anti-tumor (5) Tomaras GD, Foster DA, Burrer CM et al. J Leukoc Biol 1999 66 (1): 183-93 Another way to treat tumors It interferes with the metabolism of polyamines. Because the growth of eukaryotic cells requires that the multi-SSAT gene product is a rate-limiting enzyme for polyamine metabolism, NRF2, a homologue of GABP, can interact with the PRE of the SSAT gene. The combination of response elements promotes the transcription of the SSAT gene. (6) Yan l in Wang, Le i Xiao, Aruntha th i Th iaga l ingam (1998) J Bio l Chem 273 (51) 34623-34630. Disclosure of invention

It is an object of the present invention to provide isolated novel polypeptides-transcriptional activator protein subunit 49 and fragments, analogs and derivatives thereof.

Another object of the invention is to provide a polynucleotide encoding the polypeptide.

It is another object of the present invention to provide a recombinant vector containing a polynucleotide encoding a transcriptional activator protein subunit 49.

Another object of the present invention is to provide a genetically engineered host cell containing a polynucleotide encoding a transcriptional activator protein subunit 49.

Another object of the present invention is to provide a method for producing a transcriptional activator protein subunit 49.

It is another object of the present invention to provide antibodies against the polypeptide-transcription-activating protein subunit 49 of the present invention.

Another object of the present invention is to provide mimetic compounds, antagonists, agonists, and inhibitors of the transcription-activating protein subunit 49 of the polypeptide of the present invention.

Another object of the present invention is to provide a method for diagnosing and treating diseases associated with abnormalities in transcriptional activator subunit 49. In a first aspect of the present invention, a novel isolated transcriptional activator protein subunit 49 is provided. The polypeptide is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID NO: 2, or a conservative variant polypeptide thereof, or Its active fragment, or its active derivative, analog. Preferably, the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.

In a second aspect of the present invention, there is provided a polynucleotide encoding the isolated polypeptides, the polynucleotide comprising a nucleotide sequence, the nucleotide sequence having at least { 70%} identity: (a) a polynucleotide encoding the aforementioned transcriptional activator protein subunit 49; (b) a polynucleotide complementary to the polynucleotide (a). Preferably, the polynucleotide encodes a polypeptide having the amino acid sequence shown in SEQ ID NO: 2. More preferably, the sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 293 to 1639 in SEQ II NO: 1; and (b) having a sequence of 1-1912 in SEQ ID NO: 1 Sequence of bits.

In a third aspect of the present invention, there are provided a vector containing the above polynucleotide, and a host cell transformed or transduced by the vector or a host cell directly transformed or transduced by the above polynucleotide.

Other aspects of the invention will be apparent to those skilled in the art from the disclosure of the techniques herein. As used herein, "isolated" refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances existing in the natural state. .

As used herein, "isolated transcriptional activator protein subunit 49" means that transcriptional activator protein subunit 49 is substantially free of other proteins, lipids, carbohydrates, or other substances with which it is naturally associated. Those skilled in the art can purify transcription-activating protein subunits 49 using standard protein purification techniques. Substantially pure peptides produce a single main band on a non-reducing polyacrylamide gel. The purity of Transcription Activator Subunit 49 peptide can be analyzed by amino acid sequence.

The present invention provides a new polypeptide, a transcription activation protein subunit 49, which basically consists of the amino acid sequence shown in SEQ ID NO: 2. The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide. The polypeptides of the invention may be naturally purified products, or chemically synthesized products, or produced using recombinant techniques from prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.

The invention also includes fragments, derivatives and analogs of transcriptional activator protein subunit 49. As used in the present invention, the terms "fragment", "derivative" and "analog" refer to a polypeptide that substantially maintains the same biological function or activity of the transcriptional activating protein subunit 49 of the present invention. A fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution The amino acid may or may not be encoded by a genetic codon; or (II) a type in which a group on one or more amino acid residues is replaced by another group to include a substituent; or (Π Ι) Such a polypeptide sequence in which the mature polypeptide is fused with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol); or (IV) a polypeptide sequence in which an additional amino acid sequence is fused into the mature polypeptide (Such as a leader sequence or a secreted sequence or a sequence used to purify this polypeptide or a protease sequence) As set forth herein, such fragments, derivatives, and analogs are considered to be within the knowledge of those skilled in the art.

The present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2. The polynucleotide sequence of the present invention includes the nucleotide sequence of SEQ ID NO: 1. The polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a polynucleotide sequence of 1912 bases in length and its open reading frame (293-1639) encodes 448 amino acids. According to the amino acid sequence homology comparison, it was found that this peptide is 75% The homology can be deduced that the transcriptional activator protein subunit 49 has similar structure and function to the transcriptional activator protein GABP.

The polynucleotide of the present invention may be in the form of DNA or RM. DNA forms include cDM, genomic DNA, or synthetic DNA. DNA can be single-stranded or double-stranded. DNA can be coding or non-coding. The coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant. As used herein, a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but having a sequence different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.

The polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.

The term "polynucleotide encoding a polypeptide" refers to a polynucleotide comprising the polypeptide and a polynucleotide comprising additional coding and / or non-coding sequences.

The invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention. Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .

The invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity between the two sequences). The invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the invention under stringent conditions. In the present invention, "strict conditions" means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1 ^fl /. SDS, 6 (TC; or (2) adding denaturants during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% F i co ll, 42 ° C, etc .; Or (3) hybridization occurs only when the identity between the two sequences is at least 95%, more preferably 97%, and the polypeptide encoded by the hybridizable polynucleotide is shown in SEQ ID NO: 2 The mature polypeptide has the same biological function and activity.

The invention also relates to nucleic acid fragments that hybridize to the sequences described above. As used in the present invention, a "nucleic acid fragment" contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 cores. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques, such as PCR, to identify and / or isolate polynucleotides encoding transcriptional activator protein subunit 49.

The polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity. The specific polynucleotide sequence encoding the transcription activator protein subunit 49 of the present invention can be performed in various ways. Get. For example, polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.

The DNA fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DNA of the polypeptide.

Of the methods mentioned above, genomic DNA isolation is the least commonly used. Direct chemical synthesis of DNA sequences is often the method of choice. The more commonly used method is the isolation of cDNA sequences. The standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library. There are many mature techniques for extracting mRNA, and kits are also commercially available (Qiagene). The construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989). Commercially available cDNA libraries are also available, such as different cDNA libraries from CI on tech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.

The genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (l) DNA-DNA or DNA-RNA hybrids; (2) the presence or absence of marker gene functions; (3) determining the level of transcripts of transcription-activating protein subunit 49; (4) ) Detection of protein products expressed by genes through immunological techniques or determination of biological activity. The above methods can be used singly or in combination.

In the method (1), the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides. In addition, the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides. The probe used here is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention. The genes or fragments of the present invention can of course be used as probes. DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).

In the (4) method, immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect protein products expressed by the transcriptional activating protein subunit 49 gene.

A method using PCR to amplify DNA / RNA (Saiki, et al. Science 1985; 230: 1350-1354) is preferably used to obtain the gene of the present invention. In particular, when it is difficult to obtain a full-length cDNA from a library, the RACE method (RACE_cDNA terminal rapid amplification method) may be preferably used, and the primers for PCR may be appropriately based on the polynucleotide sequence information of the present invention disclosed herein. Select and synthesize using conventional methods. The amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.

The polynucleotide sequence of the gene of the present invention or various DNA fragments and the like obtained as described above can be determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. To obtain the full-length cDNA sequence, The sequence needs to be repeated. Sometimes it is necessary to determine the CDM sequence of multiple clones in order to splice into a full-length cDNA sequence.

The present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell that is genetically engineered using the vector of the present invention or directly using the transcriptional activating protein subunit 49 coding sequence, and a recombinant technology for producing the polypeptide of the present invention method.

In the present invention, the polynucleotide sequence encoding the transcriptional activating protein subunit 49 can be inserted into a vector to constitute a recombinant vector containing the polynucleotide of the present invention. The term "vector" refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art. Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors (Rosenberg, eta l. Gene, 1987, 56: 125) expressed in bacteria; pMSXND expression vectors expressed in mammalian cells ( Lee and Na thans, J Bio Chem. 263: 3521, 1988) and baculovirus-derived vectors expressed in insect cells. In short, as long as it can be replicated and stabilized in the host, any plasmid and vector can be used to construct a recombinant expression vector. An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.

Methods well known to those skilled in the art can be used to construct expression vectors containing a DNA sequence encoding a transcriptional activator protein subunit 49 and appropriate transcriptional / translational regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Mo l ecu l ar C l on ing, a Labora tory Manua l, co ld Spr ing Harbor Labora tory. New York, 1989 ). The DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the l ac or trp promoter of E. coli; the PL promoter of lambda phage; eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, and the early and late SV40 promoters Promoters, retroviral LTRs, and other known promoters that control the expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenovirus enhancers.

In addition, the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture. Fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.

Those of ordinary skill in the art will know how to select an appropriate vector / transcription regulatory element (such as Promoters, enhancers, etc.) and selectable marker genes.

In the present invention, a polynucleotide encoding a transcription activator protein subunit 49 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetically engineered host cell containing the polynucleotide or a recombinant vector. The term "host cell" refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E. coli, Streptomyces; bacterial cells such as Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells such as fly S2 or Sf 9; animal cells such as CH0, COS, or Bowes s melanoma cells, etc. .

Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as E. coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the ^ (12 ₎ method. The steps used are well known in the art. Alternatively, MgC l _2. If necessary, transformation can also be performed by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and lipid Plastid packaging, etc.

Using conventional recombinant DNA technology, the polynucleotide sequence of the present invention can be used to express or produce a recombinant transcriptional activator protein subunit 49 (Scence, 1984; 224: 1431). Generally there are the following steps:

(1) using the polynucleotide (or variant) encoding the human transcriptional activating protein subunit 49 of the present invention, or transforming or transducing a suitable host cell with a recombinant expression vector containing the polynucleotide;

(2) culturing host cells in a suitable medium;

(3) Isolate and purify protein from culture medium or cells.

In step (2), depending on the host cell used, the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

In step (3), the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell. If desired, recombinant proteins can be separated and purified by various separation methods using their physical, chemical and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods. Brief description of the drawings

The following drawings are used to illustrate specific embodiments of the present invention, but not to limit the scope of the claims. Defining the scope of the invention.

Figure 1 is a comparison diagram of the amino acid sequence homology of the transcription activator protein subunit 49 and the transcription activator protein GABP of the present invention. The upper sequence is transcription activation protein subunit 49, and the lower sequence is transcription activation protein GABP. Identical amino acids are represented by single-character amino acids between the two sequences, and similar amino acids are represented by "+".

Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated transcriptional activating protein subunit 49. 49kDa is the molecular weight of the protein. The arrow indicates the isolated protein band. The best way to implement the invention

The present invention is further described below with reference to specific embodiments. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. In the following examples, the experimental methods without specific conditions are generally performed according to conventional conditions such as those described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer Suggested conditions.

Example 1: Cloning of Transcription Activator Subunit 49

Human fetal brain total RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform. Using Quik raRNA Isolation Kit

(Qiegene) Isolate poly (A) mRNA from total RNA. 2ug poly (A) mRNA is reverse transcribed to form cDNA. Use Smart cDNA Cloning Kit (purchased from Clontech). The 0 ^ fragment was inserted into the multicloning site of the pBSK (+) vector (Clontech), and transformed into DH5 ot. The bacteria formed a cDNA library. The Dye terminate cycle reaction ion sequencing kit (Perkin-Elmer) and ABI 377 automatic sequencer (Perkin-Elmer) were used to determine the sequences at the 5 'and 3' ends of all clones. The determined cDNA sequence was compared with the existing public DNA sequence database (Genebank), and it was found that the cDNA sequence of one of the clones 0635G04 was new DNA. The inserted cDNA fragments contained in this clone were determined in both directions by synthesizing a series of primers. The results showed that the full-length cDNA contained in the 0635G04 clone was 1912bp (as shown in Seq IDN0: 1), and there was a 1346bp open reading frame (0RF) from 293bp to 1639bp, which encodes a new protein (such as Seq ID NO: 2). We named this clone pBS-0635G04, and the encoded protein was named transcriptional activator protein subunit 49. Example 2: Homologous search of cDNA clones

The Bactiv program (Basiclocal Alignment search tool) was used for the sequence of transcription activation protein subunit 49 of the present invention and its encoded protein sequence [Altschul, SF et al. J. Mol. Biol. 1990; 215: 403-10] Perform homology search in Genbank, Swissport and other databases. The gene most homologous to the transcriptional activator protein subunit 49 of the present invention is a known transcriptional activator protein GABP, the accession number of the encoded protein in Genbank is M74516. The protein homology results are shown in Figure 1. The two are highly homologous, with 70% identity; 75% similarity. Example 3: Cloning of a gene encoding transcriptional activator protein subunit 49 by RT-PCR

CDNA was synthesized using fetal brain cell total RNA as a template and oligo-dT as a primer for reverse transcription reaction.

After purification of Qiagene's kit, PCR amplification was performed with the following primers:

Primerl: 5, — GCATTTTGTTGCCTCTGTTTCTC — 3, (SEQ ID NO: 3)

Primer2: 5,-CATGCAGTATTCTTTTACTTCTA- 3, (SEQ ID NO: 4)

Primerl is a forward sequence located at the 5th end of SEQ ID NO: 1, starting at lbp;

Primer2 is the 3 'end reverse sequence in SEQ ID NO: 1.

Conditions for the amplification reaction: 50 mmol / L KC1, 10 mmol / L Tris-CI, (pH 8.5), 1.5 ramol / L MgCl ₂ , 200 μ mol / L dNTP, lOpmol primers in a 50 μ 1 reaction volume, 1U of Taq DNA polymerase (Clontech). The reaction was performed on a PE9600 DNA thermal cycler (Perkin-Elmer) for 25 cycles under the following conditions: 94. C 30sec; 55 ° C 30sec; 72. C 2min. During RT-PCR, set β-act in as a positive control and template blank as a negative control. The amplified product was purified using a QIAGEN kit and ligated to a PCR vector using a TA cloning kit (Invitrogen). The DNA sequence analysis results showed that the DNA sequence of the PCR product was exactly the same as the 1- 1912bp shown in SEQ ID NO: 1. Example 4: Analysis of Transcription Activator Subunit 49 Gene Expression by Northern Blotting:

Total RNA extraction in one step [Anal. Biochem 1987, 162, 156-159]. This method involves acid guanidinium thiocyanate phenol-chloroform extraction. That is, the tissue is homogenized with 4M guanidinium isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0), and 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1 ) And centrifuge after mixing. Aspirate the aqueous layer, add isopropanol (0.8 vol) and centrifuge the mixture to obtain RNA precipitate. The resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water. Using 20 g of RNA, electrophoresis was performed on a 1.2% agarose gel containing 20 mM 3- (N-morpholino) propanesulfonic acid (ρ 7.0)-5raM sodium acetate-1 mM EDTA-2.2M formaldehyde. It was then transferred to a nitrocellulose membrane. Preparation cc- ³² P dATP with ³² P- DNA probe labeled by the random primer method. The DNA probe used was the PCR-encoded transcription-activating protein subunit 49 coding region sequence (293bp to 1639bp) shown in FIG. 1. A 32P-labeled probe (about 2 x 10 ⁶ cpm / ml) was hybridized with a nitrocellulose membrane to which RNA was transferred at 42 ° C overnight in a solution containing 50% formamide-25niM KH ₂ P0 ₄ (pH7.4)-5 x SSC-5 x Denhardt's solution and 200 μg / ml salmon sperm DNA. After hybridization, the filter was washed in 1 x SSC-0.1% SDS at 55 ° C for 30 min. Then, Phosphor Imager was used for analysis and quantification. Example 5: In vitro expression, isolation and purification of recombinant transcriptional activator protein subunit 49 According to SEQ ID NO: 1 and the coding region sequence shown in FIG. 1, a pair of specific amplification primers is designed, and the sequences are as follows:

Primer3: 5'-CCCCATATGATGTCTTTGGTGGACTTGGGAAAG-3 '(Seq ID No: 5) Primer4: 5'-CATGGATCCTTAAGATGAAACAGTTGCCATGGA-3' (Seq ID No: 6) The 5 'ends of these two primers contain Ndel and BamHI restriction sites, respectively. The coding sequences of the 5 'end and 3' end of the gene of interest are followed, respectively. The Nde I and BamH I restriction sites correspond to the expression vector plasmid pET- 28 b (+) (Novagen product, Cat. No. 69865.3) Selective endonuclease site. The pBS-0635G04 plasmid containing the full-length target gene was used as a template for the PCR reaction. The PCR reaction conditions are as follows: a total volume of 50 μ1 containing 10 pg of _P BS-0635G04 plasmid, bow | 卩 1 ^ 1116]: -3 and? ]: 11116]: -4 points and another!] Is 1 (^ 11101, Advantage polymerase Mix (Clontech)) 1 μ 1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68. C 2 min, a total of 25 The digestion product and plasmid pET-28 (+) were double-digested with Ncol and BamHI, respectively, and large fragments were recovered and ligated with T4 ligase. The ligation products were transformed with the calcium chloride method Escherichia coli DH50. After the LB plates containing kanamycin (final concentration 30 g / ml) were cultured overnight, the positive clones were screened by colony PCR and sequenced. The positive clones with the correct sequence were selected (pET-0635G04). The plasmid was transformed into E. coli BL21 (DE3) plySs (product of Novagen). In a LB liquid medium containing kanamycin (final concentration 30 g / ml), the host strain BL21 (pET-0635G04) was cultured at 37 ° C to In the logarithmic growth phase, add IPTG to a final concentration of 1 foot ol / L, and continue to cultivate for 5 hours. Centrifuge the bacteria to collect, centrifuge the bacteria, collect the supernatant by centrifugation, and combine with 6 histidine (6His-Tag) Affinity chromatography column His. Bind Quick Cartridge (product of Novagen) The purified target protein transcription-activating protein subunit 49 was obtained. After SDS-PAGE electrophoresis, a single band was obtained at 49 kDa (Figure 2). The band was transferred to a PVDF membrane and the N-terminal amino acid was subjected to the Edams hydrolysis method. Sequence analysis showed that the 15 amino acids at the N-terminus were completely identical to the 15 amino acid residues at the N-terminus shown in SEQ ID NO: 2. Example 6 Production of anti-transcription activating protein subunit 49 antibody

Polypeptide synthesizer (product of PE company) was used to synthesize the following peptides specific to transcriptional activation protein subunit 49: NH ₂ -Met-Ser-Leu-Val-As -Leu-Gly-Lys-Arg-Leu-Leu-Glu- Ala-Ala-Arg- C00H (SEQ ID NO: 7). The polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex, respectively. For methods, see: Avrameas, et al. Immunochemistry, 1969; 6: 43. Immunize the patient with 4 mg of the above-mentioned cyanin polypeptide complex and complete Freund's adjuvant. After 15 days, use the hemocyanin polypeptide complex and incomplete Freund's adjuvant to boost the immunity once. A titer plate coated with a 15 g / ml bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum. Protein A-Sepharose was used to isolate total IgG from antibody-positive home free serum. The peptide was bound to a cyanogen bromide-activated Sepharose4B column, and anti-peptide antibodies were separated from the total IgG by affinity chromatography. Immunoprecipitation demonstrated that purified antibodies specifically bind to transcriptional activator protein subunits Bit 49 is combined. Industrial applicability

The polypeptides of the present invention, as well as the antagonists, agonists and inhibitors of the polypeptides, can be directly used in the treatment of diseases, for example, they can treat muscular dystrophy, reproductive dysfunction, tumors and the like.

It has been discovered that GABP is an activator of the utrophin promoter. Utrophin is a nutrient protein present at the neuro-muscular junction. Therefore, GABP can increase the expression of utrophinD, so as to treat Duchenne muscular dystrophy. (3) Khurana TS, Rosmarin AG, Shang J et al. (1999) Mol Biol Cell 10 (6): 2075-86

GABP is also involved in the activation of the OTR (oxytocin receptor) gene promoter, and oxytocin mediates labor and ejaculation. Therefore GABP can be used to regulate reproductive function. (4) Hoare S, Copland J A, Wood T G et al (1999) Endocrinology 140 (5) 2268-79

In addition, GABP is also involved in the transcriptional activation of tumor necrosis factor, which is used for antitumor (5) TomarasGD, Foster DA, Burrer CM et al. J Leukoc Biol 1999 66 (1): 183-93. Another way to treat tumors is Interfering with the metabolism of polyamines. Because the growth of eukaryotic cells requires multiple SSAT gene products, which are rate-limiting enzymes for polyamine metabolism, NRF2, a homolog of GABP, can be combined with the PRE response element of the SSAT gene to promote the transcription of the SSAT gene. (6) Yanlin Wang, Lei Xiao, Arunthathi Thiagalingam (1998) J Biol Chera 273 (51) 34623-3463

The invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) transcriptional activator protein 49. Agonists increase transcriptional activating protein subunits 49 to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers. For example, mammalian cells or a membrane preparation expressing transcriptional activator protein subunit 49 can be cultured with the labeled transcriptional activator protein subunit 49 in the presence of a drug. The ability of the drug to increase or suppress this interaction is then determined.

Antagonists of Transcription Activator Subunit 49 include antibodies, compounds, receptor deletions, and the like that have been screened. Antagonists of transcription activator protein subunit 49 can bind to transcription activator protein subunit 49 and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide such that the polypeptide cannot perform biological functions.

When screening compounds as antagonists, transcriptional activator protein subunit 49 can be added to a bioanalytical assay to determine whether a compound is an antagonist by measuring the effect of the compound on the interaction between transcriptional activator protein subunit 49 and its receptor. . Receptor deletions and analogs that act as antagonists can be screened in the same manner as described above for screening compounds. Polypeptide molecules capable of binding to transcriptional activating protein subunit 49 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase Got. When screening, 49 molecules of transcriptional activator subunit should generally be labeled.

The present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies. The invention also provides antibodies directed against the transcriptional activating protein subunit 49 epitope. These antibodies include (but are not limited to): polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments generated from Fab expression libraries.

Polyclonal antibodies can be produced by directly injecting transcription-activating protein subunit49 into immunized animals (such as rabbits, mice, rats, etc.). A variety of adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant. Wait. Techniques for preparing monoclonal antibodies to transcriptional activator protein subunit 49 include, but are not limited to, hybridoma technology (Kohler and Miste in. Nature, 1975, 256: 495-497), triple tumor technology, human beta-cell hybridization Tumor technology, EBV-hybridoma technology, etc. Chimeric antibodies combining human constant regions and non-human variable regions can be produced using existing techniques (Morr et al, PNAS, 1985, 81: 6851), and existing techniques for producing single-chain antibodies (US Pa t No. 4946778) can also be used to produce single-chain antibodies against transcriptional activator protein subunit 49.

Antibodies against Transcription Activator Subunit 49 can be used in immunohistochemistry to detect Transcription Activator Subunit 49 in biopsy specimens.

Monoclonal antibodies that bind to transcriptional activator protein subunit 49 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.

Antibodies can also be used to design immunotoxins that target a particular part of the body. For example, a transcription-activating protein subunit 49 high-affinity monoclonal antibody can covalently bind to bacterial or phytotoxins (such as diphtheria toxin, ricin, ormosine, etc.). A common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds. This hybrid antibody can be used to kill transcription-activating protein subunit 49 positive cells .

The antibodies of the present invention can be used to treat or prevent diseases related to transcriptional activator protein subunit 49. Administration of an appropriate dose of antibody can stimulate or block the production or activity of transcriptional activator protein subunit 49.

The invention also relates to a diagnostic test method for quantitatively and locally detecting the level of transcriptional activator protein subunit 49. These tests are well known in the art and include FI SH assays and radioimmunoassays. The levels of Transcription Activator Subunit 49 detected in the test can be used to explain the importance of Transcription Activator Subunit 49 in various diseases and to diagnose diseases where Transcription Activator Subunit 49 plays a role.

The polypeptide of the present invention can also be used for peptide mapping analysis. For example, the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis. Polynucleotides encoding transcriptional activator protein subunit 49 can also be used for a variety of therapeutic purposes. Gene therapy techniques can be used to treat abnormal cell proliferation, development, or metabolism caused by the non-expression or abnormal / inactive expression of transcriptional activator protein subunit 49. Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant transcriptional activator protein subunit 49 to inhibit endogenous transcriptional activator protein subunit 49 activity. For example, a mutated transcriptional activator protein subunit 49 may be a shortened transcriptional activator protein subunit 49 that lacks a signaling domain, and although it can bind to downstream substrates, it lacks signaling activity. Therefore, recombinant gene therapy vectors can be used to treat diseases caused by abnormal expression or activity of transcriptional activator subunit 49. Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding a transcriptional activator protein subunit 49 into a cell. Methods for constructing a recombinant viral vector carrying a polynucleotide encoding a transcriptional activator protein subunit 49 can be found in the existing literature (Sambrook, eta l.). In addition, a recombinant polynucleotide encoding transcription activation protein subunit 49 can be packaged into liposomes and transferred into cells.

Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.

Oligonucleotides (including antisense RNA and DNA) and ribozymes that inhibit transcription activation protein subunit 49 mRNA are also within the scope of the present invention. A ribozyme is an enzyme-like RNA molecule that specifically decomposes specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation. Antisense RNA, DNA, and ribozymes can be obtained using any existing RM or DNA synthesis technology. For example, solid-phase phosphoramidite chemical synthesis to synthesize oligonucleotides has been widely used. Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA. This DNA sequence has been integrated downstream of the vector's RNA polymerase promoter. In order to increase the stability of the nucleic acid molecule, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphate thioester or peptide bonds instead of phosphodiester bonds.

A polynucleotide encoding transcriptional activator protein subunit 49 can be used to diagnose diseases associated with transcriptional activator protein subunit 49. A polynucleotide encoding transcriptional activator protein subunit 49 can be used to detect the expression of transcriptional activator protein subunit 49 or the abnormal expression of transcriptional activator protein subunit 49 in a disease state. For example, a DNA sequence encoding transcriptional activator protein subunit 49 can be used to hybridize biopsy specimens to determine the expression of transcriptional activator protein subunit 49. Hybridization techniques include Southern blotting, Nor thern blotting, and in situ hybridization. These techniques and methods are publicly available and mature, and related kits are commercially available. A part or all of the polynucleotides of the present invention can be used as probes to be fixed on a micro array or a DM chip (also called a "gene chip") for analyzing differential expression analysis of genes and genetic diagnosis in tissues. Performed with primers specific for transcription activator subunit 49 RNA-polymerase chain reaction (RT-PCR) in vitro amplification can also detect the transcription products of transcription-activating protein subunit 49.

Detection of mutations in the transcriptional activator subunit 49 gene can also be used to diagnose diseases associated with the transcriptional activator subunit 49. Transcription activator subunit 49 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type transcription activation protein subunit 49 DNA sequence. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression, so Northern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.

The sequences of the invention are also valuable for chromosome identification. The sequence specifically targets a specific position on a human chromosome and can hybridize to it. Currently, specific sites for each gene on the chromosome need to be identified. Currently, only a few chromosome markers based on actual sequence data (repeating polymorphisms) are available for marking chromosome positions. According to the present invention, in order to associate these sequences with disease-related genes, an important first step is to locate these DNA sequences on a chromosome.

In short, PCR primers (preferably 15-35bp) are prepared based on cDNA, and the sequences can be located on chromosomes. These primers were then used for PCR screening of somatic hybrid cells containing individual human chromosomes. Only those heterozygous cells containing the human gene corresponding to the primer will produce amplified fragments.

PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes. Using the oligonucleotide primers of the present invention, in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization. Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.

Fluorescent in situ hybridization (FISH) of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).

Once the sequence is located at the exact chromosomal location, the physical location of the sequence on the chromosome can be correlated with the genetic map data. These data can be found in, for example, V. Mckusick, Mendeian Inheritance in Man (available online with Johns Hopkins University Welch Medical Library). Linkage analysis can then be used to determine the relationship between genes and diseases that have been mapped to chromosomal regions.

Next, the differences in cDNA or genomic sequences between the affected and unaffected individuals need to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease. Comparing diseased and unaffected individuals usually involves first looking for structural changes in the chromosome, such as defects visible at the chromosomal level or detectable by cDNA sequence-based PCR Missing or transposing. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).

The polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier. These carriers can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof. The composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.

The invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention. Along with these containers, there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell. In addition, the polypeptides of the invention can be used in combination with other therapeutic compounds.

The pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration. Transcription activator protein subunit 49 is administered in an amount effective to treat and / or prevent a specific indication. The amount and dose range of Transcription Activator Subunit 4.9 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician.

Table

(1) General information:

(ii) Title of Invention: Transcription activator protein subunit 49 and its coding sequence

(iii) Number of sequences: 7

(2) Information of SEQ ID NO: 1:

(i) Sequence characteristics:

(A) Length: 1912bp

(B) Type: Nucleic acid

(C) Chain: double strand

(D) Topological structure: linear

(ii) Molecular type: cDNA

(xi) Sequence description: SEQ ID NO: 1:

TTTCTTGGCTCATATCATTGCTTTAAACATAGAAGTAAAAGAATACTGCATG

(3) Information of SEQ ID NO: 2:

(i) Sequence characteristics:

(A) Length: 448 amino acids

(B) Type: Amino acid

(D) Topological structure: linear

(ii) Molecular type: peptide

(xi) Sequence description: SEQ ID NO: 2:

Met Ser Leu Val Asp Leu Gly Lys Arg Leu Leu Glu Ala Ala Arg

Lys Gly Gin Asp Asp Glu Val Arg Thr Leu Met Ala Asn Gly Ala

Pro Phe Thr Thr Asp Trp Leu Gly Thr Ser Pro Leu His Leu Ala

Ala Gin Tyr Gly His Tyr Ser Thr Ala Glu Val Leu Leu Arg Ala

Gly Val Ser Arg Asp Ala Arg Thr Lys Val Asp Arg Thr Pro Leu

His Met. Ala Ala Ala Asp Gly His Ala His lie Val Glu Leu Leu

VaJ Arg Asn Gly Ala Asp Val Asn Ala Lys A, sp Met Leu Lys Met

T r Ala Leu His Trp Ala Thr Glu Arg His His Arg Asp Val Val

Glu Leu Leu lie Lys Tyr Gly Ala Asp Val His Ala Phe Ser Lys

Phe Asp Lys Ser Ala Phe Asp lie Ala Leu Glu Lys Asn Asn Ala

Glu lie Leu Val lie Leu Gin Glu Ala Met Gin Asn Gin Val Asn

Val As ii Pro Glu Arg Ala Asn Pro Val Thr Asp Pro Val Ser Met

Ala Ala Pro Phe lie Phe Thr Ser Gly Glu Val Val Asn Leu Ala 196 Ser Leu lie Ser Ser Thr Asn Thr Lys Thr Thr Ser Gly Asp Pro

211 His Ala Ser Thr Val Gin Phe Ser Asn Ser Thr Thr Ser Val Leu

226 Ala Thr Leu Ala Ala Leu Ala Glu Ala Ser Val Pro Leu Ser Asn

241 Ser His Arg Ala Thr Ala Asn Thr Glu Glu He lie Glu Gly Asn

256 Ser Val Asp Ser Ser lie Gin Gin Val Met Gly Ser Gly Gly Gin

271 Arg Val lie Thr lie Val Thr Asp Gly Val Pro Leu Gly Asn lie

286 Gin bill

Thr Ser lie Pro Thr Gly Gly lie Gly Gin Pro Phe lie Val

301 Thr Val Gin Asp Gly Gin Gin Val Leu Thr Val Pro Ala Gly Lys

316 Val Ala Glu Glu Thr Val lie Lys Glu Glu Glu Glu Glu Lys Leu] Pro Leu Thr Lys Lys Pro Arg He Gly Glu Lys Thr Asn Ser Val

346 Glu Glu Ser Lys Glu Gly Asn Glu Arg Glu Leu Leu Gin Gin Gin

361 Leu Gin Glu Ala Asn Arg Arg Ala Gin Glu Tyr Arg His Gin Leu

376 Leu Lys Lys Glu Gin Glu Ala Glu Gin Tyr Arg Leu Lys Leu Glu

391 Ala lie Ala Arg Gin Gin Pro Asn Gly Val A Phe Thr MP † Val

406 Glu Glu Val Ala Glu Val Asp Ala Val Val Val Thr Glu Gly Glu

421 Leu Glu Glu Arg Gly Thr Lys Val Thr Gly Ser Ala Gly Thr Thr

436 Glu Pro His Thr Arg Val Ser Met Ala Thr Val Ser Ser

(4) Information of SEQ ID NO: 3

(i) Sequence characteristics

(A) Length: 23 bases

(B) Type: Nucleic acid

(C) Chain: single chain

(D) Topological structure: linear

(Π) Molecular type: Oligonucleotide

(xi) Sequence description: SEQ ID NO: 3:

GCATTTTGTTGCCTCTGTTTCTC

(5) Information of SEQ ID NO: 4

(i) Sequence characteristics

(A) Length: 23 bases

(B) Type

(C) Chainability (D) Topological structure: linear

(Π) Molecular type: Oligonucleotide

(xi) Sequence description: SEQ ID NO: 4:

CATGCAGTATTCTTTTACTTCTA

(6) Information of SEQ ID NO: 5

(i) Sequence characteristics

(A) Length: 33 bases

(B) Type: Nucleic acid

(C) Chain: single chain

(W topology: linear

(ii) Molecular type: Oligonucleotide

(xi) Sequence description: SEQ ID NO: 5:

CCCCATATGATGTCTTTGGTGGACTTGGGAAAG 33

(7) Information of SEQ ID NO: 6

(i) Sequence characteristics

(A) Length: 33 bases

(B) Type: Nucleic acid

(C) Chain: single chain

(D) Topological structure: linear

(ii) Molecular type: Oligonucleotide

(xi) Sequence description: SEQ ID NO: 6:

CATGGATCCTTAAGATGAAACAGTTGCCATGGA 33

(8) Information of SEQ ID NO: 7:

(i) Sequence characteristics:

(A) Length: 15 amino acids

(B) Type: Amino acid

(D) Topological structure: linear

(Π) Molecular type: Polypeptide

(xi) Sequence description: SEQ ID NO: 7:

Met-Ser-Leu-Val-Asp-Leu-Gly-Lys-Arg-Leu-Leu-G 1 u— A 1 a-Ala-Arg

Claims

Claim

1. An isolated polypeptide-transcription-activating protein subunit 49, characterized in that it comprises: a polypeptide having the amino acid sequence shown in SEQ ID NO: 2, or an active fragment, analog, or derivative thereof.

2. The polypeptide according to claim 1, characterized in that the amino acid sequence of the polypeptide, analog or derivative has at least 95% identity with the amino acid sequence shown in SEQ ID NO: 2.

3. The polypeptide according to claim 2, further comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 2.

4. An isolated polynucleotide, characterized in that said polynucleotide comprises one selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide having the amino acid sequence shown in SEQ ID NO: 2 or a fragment, analog, or derivative thereof;

(b) a polynucleotide complementary to polynucleotide (a); or

(c) A polynucleotide that is at least 70% identical to (a) or (b).

5. The polynucleotide according to claim 4, wherein the polynucleotide comprises a polynucleotide encoding an amino acid sequence represented by SEQ ID NO: 2.

6. The polynucleotide according to claim 4, characterized in that the sequence of said polynucleotide comprises the sequence of positions 293-1639 in SEQ II) NO: 1 or the sequence of positions 1-1912 in SEQ ID NO: 1 sequence.

7. A recombination vector containing an exogenous polynucleotide, characterized in that it is a recombination constructed by the polynucleotide according to any one of claims 4-6 and a plasmid, virus or a carrier expression vector Carrier.

8. A genetically engineered host cell containing an exogenous polynucleotide, characterized in that it is selected from one of the following host cells:

(a) a host cell transformed or transduced with the recombinant vector of claim 7; or

(b) a host cell transformed or transduced with a polynucleotide according to any one of claims 4-6.

9. A method for preparing a polypeptide having transcriptional activating protein subunit 49 activity, characterized in that the method comprises:

(a) culturing the engineered host cell according to claim 8 under the condition of expressing transcription activator protein subunit 49;

(b) Isolating a polypeptide with transcriptional activator protein subunit 49 activity from the culture.

10. An antibody capable of binding to a polypeptide, characterized in that the antibody is an antibody capable of specifically binding to transcription activation protein subunit 49.

11. A class of compounds that mimic or regulate the activity or expression of a polypeptide, characterized in that they are compounds that mimic, promote, antagonize or inhibit the activity of transcriptional activator protein subunit 49.

12. The compound according to claim 11, characterized in that it is an antisense sequence of a polynucleotide sequence or a fragment thereof as shown in SEQ ID NO: 1.

13. The use of the compound according to claim 11, characterized in that the compound is used for a method for regulating the activity of transcription-activating protein subunit 49 in vivo and in vitro.

14. A method for detecting a disease or susceptibility to a disease associated with a polypeptide according to any one of claims 1-3, characterized in that it comprises detecting the expression level of the polypeptide, or detecting the activity of the polypeptide Or detecting a nucleotide variation in a polynucleotide that causes abnormal expression or activity of the polypeptide.

15. Use of a polypeptide according to any one of claims 1-3, characterized in that it is used for screening mimetics, agonists, antagonists or inhibitors of transcriptional activating protein subunit 49; or for peptides Fingerprint identification.

16. The use of a nucleic acid molecule according to any one of claims 4-6, characterized in that it is used as a primer for a nucleic acid amplification reaction, or as a probe for a hybridization reaction, or for manufacturing a gene chip Or microarray.

17. Use of a polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that the polypeptide, polynucleotide or mimetic, agonist, antagonist is used Or the inhibitor is composed of a safe and effective dose with a pharmaceutically acceptable carrier as a pharmaceutical composition for diagnosing or treating a disease associated with the abnormality of transcription activator subunit 49.

18. Use of a polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that the polypeptide, polynucleotide or compound is used for the preparation of a treatment such as muscular dystrophy, Reproductive disorders, tumor drugs.